OMCAZIO (Cabozantinib Laurylsulfate) Patent Expiration, LOE Window & CMS Spending

OMCAZIO (Cabozantinib Laurylsulfate) by Handa Oncology: FDA Orange Book core substance LOE 2044-01-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHanda Oncology
FDA Application & PathwayN220613 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2044-01-30
Last Listed Patent or Exclusivity Date2044-01-30
Orange Book Patents (*PED Extensions)39 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel